Altaris Capital Acquires Veranova (Johnson Matthey Health business)
June 1, 2022
Altaris Capital Partners completed the acquisition of Veranova (formerly Johnson Matthey's Health business) from Johnson Matthey PLC for total consideration of up to £325 million, with Johnson Matthey retaining approximately a 30% equity stake. Veranova is a global CDMO focused on specialty and complex active pharmaceutical ingredients (APIs), headquartered in Wayne, Pennsylvania, with roughly 900 employees across seven development and manufacturing sites in North America, Europe and Asia.
- Buyers
- Altaris Capital Partners, LLC
- Targets
- Veranova (formerly Johnson Matthey's Health business)
- Sellers
- Johnson Matthey PLC
- Industry
- Pharmaceuticals
- Location
- Pennsylvania, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Altaris Capital Partners Acquires Kindeva Drug Delivery from 3M
May 1, 2020
Medical Devices
Altaris Capital Partners has acquired Kindeva Drug Delivery L.P. (formerly 3M Drug Delivery Systems) from 3M Company for $650 million in a corporate carve-out transaction. Monroe Capital provided financing and an equity co-investment to support the deal, and 3M will retain a minority interest alongside Altaris as Kindeva operates independently to pursue growth and capital investments.
-
Altaris Combines Kindeva Drug Delivery and Meridian Medical Technologies
December 13, 2022
Medical Devices
Altaris has completed the combination of its portfolio companies Kindeva Drug Delivery and Meridian Medical Technologies into a single, global drug‑device CDMO that will operate under the Kindeva name. The combined company expands capabilities across parenteral, inhalation, transdermal and intradermal delivery formats; Milton Boyer (formerly Meridian CEO) will lead the combined business.
-
Altaris Capital Partners Acquires Meridian Medical Technologies from Pfizer
December 30, 2021
Medical Devices
Altaris Capital Partners has entered into an agreement to acquire Meridian Medical Technologies from Pfizer. Meridian, a pioneer in emergency response drug-device combination products and auto-injectors with facilities in St. Louis, Missouri and Columbia, Maryland and more than 750 employees, will become an Altaris portfolio company to expand the firm's capabilities in medical countermeasures and emergency response solutions.
-
ANI Pharmaceuticals Acquires Novitium Pharma for $163.5M
March 9, 2021
Pharmaceuticals
ANI Pharmaceuticals completed the acquisition of Novitium Pharma for $163.5 million (including $89.5M cash and $74M equity, plus up to $46.5M in contingent earn-outs), adding a U.S.-based R&D engine and CDMO manufacturing capacity. The deal, financed with a new $300M Term Loan B, a $40M revolver and a $25M PIPE investment from Ampersand Capital Partners, is expected to be immediately accretive and expand ANI's generics, contract manufacturing and 505(b)(2) capabilities.
-
Kindeva Drug Delivery (Altaris) Acquires Summit Biosciences
January 18, 2024
Medical Devices
Kindeva Drug Delivery, an operating company of healthcare investor Altaris, has acquired Summit Biosciences from its founding family shareholders. The acquisition adds Summit’s FDA- and EMA-approved 55,000 sq. ft. cGMP intranasal CDMO facility in Lexington, Kentucky, expanding Kindeva’s nasal drug‑delivery platform and global manufacturing footprint.
-
General Atlantic Invests in Javara
April 12, 2022
Healthcare Services
Javara, an integrated research organization that embeds clinical trials at the point of care, has secured a Series B growth investment from global growth equity firm General Atlantic. The capital will be used to drive geographic expansion and technology advancement as General Atlantic joins Javara's board to support scaling of its clinical research-as-care model.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.